Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm
| العنوان: | Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm |
|---|---|
| المؤلفون: | Hugo Vrenken, Lukas Pirpamer, Alex Rovira, Richard Nicholas, Frcp Olga Ciccarelli PhD, James H. Cole, Joel Raffel, Declan T. Chard, Serena Ruggieri, Nicola De Stefano, Christian Enzinger, Frederik Barkhof, Arman Eshaghi, Bernard M. J. Uitdehaag, Jaume Sastre-Garriga, Maria A. Rocca, Tim Friede, Maria Laura Stromillo, Fean Massimo Filippi Md, Fracp Wallace J. Brownlee PhD, Claudio Gasperini |
| المساهمون: | Amsterdam Neuroscience - Neuroinfection & -inflammation, Neurology, Radiology and nuclear medicine, Cole, Jh, Raffel, J, Friede, T, Eshaghi, A, Brownlee, Wj, Chard, D, De Stefano, N, Enzinger, C, Pirpamer, L, Filippi, M, Gasperini, C, Rocca, Ma, Rovira, A, Ruggieri, S, Sastre-Garriga, J, Stromillo, Ml, Uitdehaag, Bmj, Vrenken, H, Barkhof, F, Nicholas, R, Ciccarelli, O, MAGNIMS study, Group |
| المصدر: | Annals of Neurology, 88(1), 93-105. John Wiley and Sons Inc. Cole PhD, J H, Raffel MD, J, Friede PhD, T, Eshaghi MD, PhD, A, Brownlee PhD, FRACP, W J, Chard MD, PhD, D, De Stefano MD, PhD, N, Enzinger MD, C, Pirpamer MSc, L, Filippi MD, FEAN, M, Gasperini MD, C, Rocca MD, M A, Rovira MD, A, Ruggieri MD, S, Sastre-Garriga MD, PhD, J, Stromillo MD, PhD, M L, Uitdehaag MD, PhD, B M J, Vrenken PhD, H, Barkhof MD PhD, F, Nicholas MD, PhD, R & Ciccarelli PhD, FRCP, O 2020, ' Longitudinal Assessment of Multiple Sclerosis with the Brain-Age Paradigm ', Annals of Neurology, vol. 88, no. 1, pp. 93-105 . https://doi.org/10.1002/ana.25746Test |
| سنة النشر: | 2019 |
| مصطلحات موضوعية: | 0301 basic medicine, Adult, Male, medicine.medical_specialty, Aging, Multiple Sclerosis, Adolescent, 03 medical and health sciences, Disability Evaluation, Young Adult, 0302 clinical medicine, Atrophy, Internal medicine, medicine, Humans, Longitudinal Studies, 10. No inequality, Aged, Clinically isolated syndrome, Expanded Disability Status Scale, medicine.diagnostic_test, business.industry, Multiple sclerosis, Hazard ratio, Brain, Magnetic resonance imaging, Middle Aged, medicine.disease, Demyelinating Diseases, Disease Progression, Female, Confidence interval, Clinical trial, 030104 developmental biology, Neurology, Neurology (clinical), business, 030217 neurology & neurosurgery |
| الوصف: | Objective: During the natural course of multiple sclerosis (MS), the brain is exposed to aging as well as disease effects. Brain aging can be modeled statistically; the so-called “brain-age” paradigm. Here, we evaluated whether brain-predicted age difference (brain-PAD) was sensitive to the presence of MS, clinical progression, and future outcomes. Methods: In a longitudinal, multicenter sample of 3,565 magnetic resonance imaging (MRI) scans, in 1,204 patients with MS and clinically isolated syndrome (CIS) and 150 healthy controls (mean follow-up time: patients 3.41 years, healthy controls 1.97 years), we measured “brain-predicted age” using T1-weighted MRI. We compared brain-PAD among patients with MS and patients with CIS and healthy controls, and between disease subtypes. Relationships between brain-PAD and Expanded Disability Status Scale (EDSS) were explored. Results: Patients with MS had markedly higher brain-PAD than healthy controls (mean brain-PAD +10.3 years; 95% confidence interval [CI] = 8.5–12.1] versus 4.3 years; 95% CI = 2.1 to 6.4; p < 0.001). The highest brain-PADs were in secondary-progressive MS (+13.3 years; 95% CI = 11.3–15.3). Brain-PAD at study entry predicted time-to-disability progression (hazard ratio 1.02; 95% CI = 1.01–1.03; p < 0.001); although normalized brain volume was a stronger predictor. Greater annualized brain-PAD increases were associated with greater annualized EDSS score (r = 0.26; p < 0.001). Interpretation: The brain-age paradigm is sensitive to MS-related atrophy and clinical progression. A higher brain-PAD at baseline was associated with more rapid disability progression and the rate of change in brain-PAD related to worsening disability. Potentially, “brain-age” could be used as a prognostic biomarker in early-stage MS, to track disease progression or stratify patients for clinical trial enrollment. ANN NEUROL 2020 ANN NEUROL 2020;88:93–105. |
| تدمد: | 1531-8249 0364-5134 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0257252c53d69079c1a8c71d16ff551dTest https://pubmed.ncbi.nlm.nih.gov/32285956Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....0257252c53d69079c1a8c71d16ff551d |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15318249 03645134 |
|---|